Clinical Trial Update: A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating patient preference and satisfaction with subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in HER…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab + Trastuzumab (fixed-dose subcutaneous combination)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HER2-Positive Early Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-04-26